Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31368701 | 1.00 | HTR3A (0.55) | HTR3AHTR2ASLC6A4HRH1PDE4D | |
| SCHEMBL7290934 | 0.88 | HTR3A (0.55) | HTR3AHTR2ASLC6A4HRH1PDE4D | |
| SCHEMBL7281271 | 0.88 | HTR3A (0.71) | HTR3AHTR2ASLC6A4HRH1PDE4D | |
| Hydrochloric Acid SCHEMBL7288488 | 0.87 | HTR3A (0.70) | HTR3AHTR2ASLC6A4HRH1PDE4D | |
| SCHEMBL7375497 | 0.84 | HTR3A (0.50) | HTR3AHTR2ASLC6A4HRH1PDE4D | |
| SCHEMBL7287895 | 0.80 | HTR3A (0.55) | HTR3AHTR2ASLC6A4HRH1PDE4D | |
| SCHEMBL7269264 | 0.77 | HTR3A (0.45) | HTR3AHTR2ASLC6A4HRH1PDE4D | |
| SCHEMBL7281518 | 0.77 | HTR3A (0.49) | HTR3AHTR2ASLC6A4HRH1PDE4D | |
| SCHEMBL7282389 | 0.76 | HTR3A (0.68) | HTR3AHTR2ASLC6A4HRH1PDE4D | |
| SCHEMBL31387625 | 0.76 | HTR3A (0.68) | HTR3AHTR2ASLC6A4HRH1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170139-A1 | AZASETRON FOR THE TREATMENT OF SUDDEN SENSORINEURAL HEARING LOSS | SENSORION (FR) | 2025-05-29 | — | — | US | claimed |
| WO-2023175078-A1 | AZASETRON FOR THE TREATMENT OF SUDDEN SENSORINEURAL HEARING LOSS | SENSORION (FR) | 2023-09-21 | — | — | WO | claimed |
| US-20220387438-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | SENSORION (FR) | 2022-12-08 | — | — | US | claimed |
| EP-3909579-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | Sensorion (FR) | 2021-11-17 | — | — | EP | claimed |
| US-20180207167-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | SENSORION (FR) | 2018-07-26 | — | — | US | claimed |
| EP-3297628-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | Sensorion (FR) | 2018-03-28 | — | — | EP | claimed |
| WO-2016184900-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | SENSORION (FR) | 2016-11-24 | — | — | WO | claimed |
| EP-0313393-B1 | Benzoxazine compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL (JP) | 1994-03-16 | — | — | EP | claimed |
| US-4892872-A | ANTIEMETICS, ANTINAUSEA | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-01-09 | — | — | US | claimed |
| EP-0313393-A2 | Benzoxazine compounds and pharmaceutical use thereof | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1989-04-26 | — | — | EP | claimed |
| US-20250170139-A1 | AZASETRON FOR THE TREATMENT OF SUDDEN SENSORINEURAL HEARING LOSS | SENSORION (FR) | 2025-05-29 | — | — | US | disclosed |
| WO-2023175078-A1 | AZASETRON FOR THE TREATMENT OF SUDDEN SENSORINEURAL HEARING LOSS | SENSORION (FR) | 2023-09-21 | — | — | WO | disclosed |
| US-20220387438-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | SENSORION (FR) | 2022-12-08 | — | — | US | disclosed |
| US-11433077-B2 | Calcineurin inhibitors of the setron family for the treatment of hearing loss | SENSORION (FR) | 2022-09-06 | — | — | US | disclosed |
| US-20220265668-A1 | TREATMENT AND/OR PREVENTION OF LESIONS IN THE CENTRAL AUDITORY NERVOUS SYSTEM | SENSORION (FR) | 2022-08-25 | — | — | US | disclosed |
| EP-3297628-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | Sensorion (FR) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016184900-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | SENSORION (FR) | 2016-11-24 | — | — | WO | disclosed |
| EP-0313393-B1 | Benzoxazine compounds and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL (JP) | 1994-03-16 | — | — | EP | disclosed |
| US-4892872-A | ANTIEMETICS, ANTINAUSEA | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1990-01-09 | — | — | US | disclosed |
| EP-0313393-A2 | Benzoxazine compounds and pharmaceutical use thereof | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1989-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265668-A1 | TREATMENT AND/OR PREVENTION OF LESIONS IN THE CENTRAL AUDITORY NERVOUS SYSTEM | NLN, GAP43, RARS2 | HTR3A 1848/4885HTR2A 3948/4885SLC6A4 1900/4885 |
| US-20180207167-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | CHP1, SENP7, SENP1 | HTR3A 4099/4885HTR2A 4617/4885SLC6A4 2596/4885 |
| US-11433077-B2 | Calcineurin inhibitors of the setron family for the treatment of hearing loss | CHP1, SENP7, SENP1 | HTR3A 4099/4885HTR2A 4617/4885SLC6A4 2596/4885 |
| US-20250170139-A1 | AZASETRON FOR THE TREATMENT OF SUDDEN SENSORINEURAL HEARING LOSS | AASDHPPT, SCN3A, DNPEP | HTR3A 117/4885HTR2A 2077/4885SLC6A4 254/4885 |
| US-20220387438-A1 | CALCINEURIN INHIBITORS OF THE SETRON FAMILY FOR THE TREATMENT OF HEARING LOSS | CHP1, SENP7, SENP1 | HTR3A 4099/4885HTR2A 4617/4885SLC6A4 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.